

University of Wollongong

Research Online

Faculty of Science, Medicine and Health -
Papers: part A

Faculty of Science, Medicine and Health

1-1-2012

The heat shock response is modulated by and interferes with toxic effects of scrapie prion protein and amyloid β

Ulrike K. Resenberger
Ludwig-Maximilians-University Munich

Veronika Muller
Ludwig-Maximilians-University Munich

Lisa M. Munter
Freie University Berlin

Michael Baier
Robert-Koch-Institut, Berlin

Gerd Multhaup
Freie University Berlin, Robert-Koch-Institut, Berlin

See next page for additional authors

Follow this and additional works at: <https://ro.uow.edu.au/smhpapers>

Recommended Citation

Resenberger, Ulrike K.; Muller, Veronika; Munter, Lisa M.; Baier, Michael; Multhaup, Gerd; Wilson, Mark R.; Winklhofer, Konstanze F.; and Tatzelt, Jorg, "The heat shock response is modulated by and interferes with toxic effects of scrapie prion protein and amyloid β " (2012). *Faculty of Science, Medicine and Health - Papers: part A*. 65.

<https://ro.uow.edu.au/smhpapers/65>

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: research-pubs@uow.edu.au

The heat shock response is modulated by and interferes with toxic effects of scrapie prion protein and amyloid β

Abstract

The heat shock response (HSR) is an evolutionarily conserved pathway designed to maintain proteostasis and to ameliorate toxic effects of aberrant protein folding. We have studied the modulation of the HSR by the scrapie prion protein (PrP^{Sc}) and amyloid β peptide (A β) and investigated whether an activated HSR or the ectopic expression of individual chaperones can interfere with PrP^{Sc}- or A β -induced toxicity. First, we observed different effects on the HSR under acute or chronic exposure of cells to PrP^{Sc} or A β . In chronically exposed cells the threshold to mount a stress response was significantly increased, evidenced by a decreased expression of Hsp72 after stress, whereas an acute exposure lowered the threshold for stress-induced expression of Hsp72. Next, we employed models of PrP^{Sc}- and A β -induced toxicity to demonstrate that the induction of the HSR ameliorates the toxic effects of both PrP^{Sc} and A β . Similarly, the ectopic expression of cytosolic Hsp72 or the extracellular chaperone clusterin protected against PrP^{Sc}- or A β -induced toxicity. However, toxic signaling induced by a pathogenic PrP mutant located at the plasma membrane was prevented by an activated HSR or Hsp72 but not by clusterin, indicating a distinct mode of action of this extracellular chaperone. Our study supports the notion that different pathological protein conformers mediate toxic effects via similar cellular pathways and emphasizes the possibility to exploit the heat shock response therapeutically.

Keywords

scrapie, prion, protein, amyloid, response, modulated, interferes, toxic, heat, effects, shock, CMMB

Publication Details

Resenberger, U. K., Muller, V., Munter, L. M., Baier, M., Multhaup, G., Wilson, M. R., Winklhofer, K. F. & Tatzelt, J. (2012). The heat shock response is modulated by and interferes with toxic effects of scrapie prion protein and amyloid β . *Journal of Biological Chemistry*, 287 (52), 43765-43776.

Authors

Ulrike K. Resenberger, Veronika Muller, Lisa M. Munter, Michael Baier, Gerd Multhaup, Mark R. Wilson, Konstanze F. Winklhofer, and Jorg Tatzelt

The heat shock response is modulated by and interferes with toxic effects of scrapie prion protein and amyloid β *

Ulrike K. Resenberger¹, Veronika Müller¹, Lisa M. Munter^{2,3}, Michael Baier⁴, Gerd Multhaup^{2,3}, Mark R. Wilson⁵, Konstanze F. Winklhofer^{1,6} and Jörg Tatzelt^{1,6¶}

¹Neurobiochemistry, Adolf-Butenandt-Institute, Ludwig-Maximilians-University Munich, Germany;

²Institut für Chemie und Biochemie, Freie Universität, Berlin, Germany; ³Department of Pharmacology & Therapeutics, McGill University, Montreal, Canada; ⁴Robert-Koch-Institut, Berlin, Germany; ⁵School of Biological Sciences, University of Wollongong, New South Wales, Australia;

⁶German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

* Running title: *Heat shock response and proteotoxicity*

¶Address correspondence to: Jörg Tatzelt, Ludwig-Maximilians-University Munich, Schillerstrasse 44, D-80336 Munich, Germany; phone: +49 89 2180 75442; fax: +49 89 2180 75415; e-mail: Joerg.Tatzelt@med.uni-muenchen.de

Keywords: heat shock, chaperones, proteotoxicity, prion, amyloid β

Background:

The heat shock response (HSR) is a stress response pathway to counteract proteotoxic effects of aberrantly folded proteins.

Results:

The HSR is deregulated by PrP^{Sc} and A β and can protect against toxic effects of PrP^{Sc}, A β and a neurotoxic PrP mutant.

Conclusions:

The toxicity of different pathogenic proteins is mediated via similar cellular pathways.

Significance:

Identifying cellular pathways activated by neurotoxic proteins will help to develop therapeutic strategies.

SUMMARY

The heat shock response (HSR) is an evolutionarily conserved pathway designed to maintain proteostasis and to ameliorate toxic effects of aberrant protein folding. We have studied the modulation of the HSR by the scrapie prion protein (PrP^{Sc}) and amyloid beta peptide (A β) and investigated whether an activated HSR or the ectopic expression of individual chaperones can interfere with PrP^{Sc}- or A β -induced toxicity. First, we observed different effects on the HSR under acute or chronic exposure of cells to PrP^{Sc} or A β . In chronically exposed cells the threshold to mount a stress response was significantly increased, evidenced by a decreased expression of Hsp72 after stress, while an acute exposure lowered the threshold for

stress-induced expression of Hsp72. Next, we employed models of PrP^{Sc}- and A β -induced toxicity to demonstrate that the induction of the HSR ameliorates the toxic effects of both PrP^{Sc} and A β . Similarly, the ectopic expression of cytosolic Hsp72 or the extracellular chaperone clusterin protected against PrP^{Sc}- or A β -induced toxicity. However, toxic signaling induced by a pathogenic PrP mutant located at the plasma membrane was prevented by an activated HSR or Hsp72 but not by clusterin, indicating a distinct mode of action of this extracellular chaperone. Our study supports the notion that different pathological protein conformers mediate toxic effects via similar cellular pathways and emphasizes the possibility to exploit the heat shock response therapeutically.

Accumulation of misfolded and aggregated proteins is a hallmark of various neurodegenerative diseases. Prion diseases (rev. in (1-4)) and Alzheimer's disease (AD) (rev. in (5,6)) are characterized by extracellular protein assemblies formed by the scrapie prion protein (PrP^{Sc}) or amyloid beta (A β) peptide, respectively. Whereas prion diseases and AD are clearly distinct disease entities, there appear to be commonalities concerning structural features

of the pathogenic protein conformers as well as pathways implicated in their toxic effects (rev. in (7-10)).

The protein deposits found in AD or prion diseases are associated with intra- and extracellular heat shock proteins (Hsps) (11-13), suggesting a role of Hsps in the pathogenic process. Hsps, many of which function as molecular chaperones, comprise a class of proteins that are induced under conditions of cellular stress when the concentration of aggregation-prone folding intermediates are increasing. However, Hsps exert fundamental functions also under physiological conditions since they are vitally engaged in protein folding, trafficking and regulation of signaling pathways (rev. in (14)). Hsps are found in all cellular compartments and organelles. In addition, clusterin is a secreted chaperone shown to be involved in the extracellular protein quality control system (15). Upregulation of Hsps after acute or chronic proteotoxic damage is mediated by a highly conserved pathway denoted the heat shock response (HSR). At the molecular level, different stressors are integrated through the activation of a single transcription factor, the heat shock transcription factor 1 (HSF1), which binds to specific heat shock element (HSE) sequences present in the promoter region of inducible Hsp genes (rev. in (16,17)). An increase in Hsp levels prevents protein aggregation and facilitates correct folding of non-native proteins after cellular stress. In addition, chaperones participate in anti-apoptotic pathways (rev. in (18-20)). It is therefore not surprising that a deregulation of the HSR can contribute to the progression of various diseases.

Consequently, the HSR represents a target for therapeutic intervention in a range of diseases (rev. in (21-26)). For example, pharmacological induction of the HSR was shown to ameliorate disease progression and neuropathological alterations in mouse models of neurodegenerative diseases (27-29). Supporting a protective role of the HSR, deletion of HSF1 dramatically shortened the lifespan of scrapie-infected mice (30).

We have previously studied the HSR in scrapie-infected mouse neuroblastoma (ScN2a) cells, which offer a useful model to study certain aspects of prion diseases in cultured cells. Most importantly, ScN2a cells propagate partially protease-resistant PrP^{Sc} and infectious prions (31,32). The stress-induced expression of Hsp72 and Hsp28 is significantly impaired in ScN2a cells, whereas their uninfected counterparts are able to mount a normal stress response (33,34). Notably, we found that the impaired HSR in ScN2a cells is caused by an accelerated deactivation of HSF1 after stress and can be restored by the Hsp90-binding drug geldanamycin (34).

In this study, we characterized the impact of pathogenic protein conformers on the regulation of HSR by making use of cell culture models of PrP^{Sc}- and A β -induced toxicity. We demonstrate that PrP^{Sc} and A β have different effects on the HSR depending on whether they are applied in an acute or chronic manner to cells. Moreover, activation of the HSR or ectopic expression of individual chaperons is protective against PrP^{Sc}- and A β -induced cell death as well as the toxic activity of a pathogenic PrP mutant.

EXPERIMENTAL PROCEDURES

Plasmids, antibodies and reagents

Expression constructs have been described previously: PrP^C (35); HSE-luc (36); Hsp72 (37); Δ HSF, wtHSF (38); PrP Δ HD (35); pRc/VMV-clusterin (39). Amino acid numbers refer to mouse prion protein sequence (GenBankTM accession number NP 035300). As transfection marker the EYFP-C1 vector (Clontech) was used. The following antibodies were used: mouse monoclonal anti-PrP 3F4 antibody (40), rabbit polyclonal anti-PrP antibody A7 (41), mouse monoclonal anti-Hsp72 antibody C92 (42), mouse monoclonal anti-clusterin antibody 41D (43), mouse monoclonal anti- β -actin antibody (Sigma), rabbit polyclonal anti-active caspase-3 antibody (Promega), fluorescent dye-labeled anti-rabbit IgG antibody Alexa Fluor[®] 555 (Invitrogen), fluorescent dye-labeled anti-mouse IgG antibody Alexa Fluor[®] 555 (Invitrogen), horseradish peroxidase-conjugated anti-mouse IgG antibody (Amersham, Promega), horseradish peroxidase-conjugated anti-rabbit IgG antibody (Promega), horseradish peroxidase-conjugated anti-rat IgG antibody (Santa Cruz Biotechnology), rat monoclonal anti-A β antibody 2D8 (44), rabbit polyclonal anti-A β antibody 3552 (45). The following reagents were used: TO-PRO[®]-3 iodide (642/661) (Invitrogen), DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester). The mounting medium Mowiol (Calbiochem) was supplemented with DAPI (4',6-diamidino-2-phenylindole; Sigma-Aldrich).

Cell culture, transfection, co-culture

Cells were cultured and transfected as described earlier (35). The human SH-SY5Y cell line (DSMZ number ACC 209) is a sub-line of bone marrow biopsy-derived SK-N-SH cells. Stably transfected Chinese hamster ovary cells (CHO-7PA2) that express the familial AD mutation V717F in the amyloid precursor protein APP₇₅₁ and secrete A β were described earlier (46). Cells cultured in 3.5 cm dishes were transfected with DNA by a liposome-mediated method using LipofectAMIN Plus reagent (Invitrogen) according to the manufacturer's instructions. For co-culture experiments, SH-SY5Y cells were grown on glass coverslips. 2 h after transfection coverslips were transferred into dishes containing a 90% confluent cell layer of either ScN2a or N2a or CHO-7PA2 or CHO cells (47,48). After 16 h or 24 h of co-culture, either apoptotic cell death or luciferase activity was analyzed (see below). For stable transfection, SH-SY5Y cells were transfected with the plasmid pCEP4 containing the coding sequence for APP695 using Transfectine (Bio-Rad) according to the manufacturer's instructions. Stably transfected cells were selected with hygromycin (250 μ g/ml). The empty vector was used as control (mock-transfected).

Cell lysis, immunoprecipitation and Western blot analysis

As described earlier (49), cells were washed twice with cold phosphate-buffered saline [PBS], scraped off the plate and lysed in cold detergent buffer A (0.5% Triton X-100, 0.5% sodium deoxycholate in PBS). Total lysates or secreted and trichloroacetic acid (TCA)-precipitated proteins were boiled with Laemmli sample buffer and analyzed by Western blotting

as described previously (50). For proteolysis experiments, lysates of ScN2a or N2a cells were digested with Proteinase K for 30 min at 37°C (final concentration 10 µg/ml). Reaction was stopped by the addition of PMSF (final concentration 2 mM) and PrP analyzed by Western blotting using the polyclonal anti-PrP antibody A7. Aβ in conditioned medium of CHO-7PA2 cells or stably transfected SH-SY5Y cells were analyzed by immunoprecipitation with the polyclonal antibody 3552 followed by Western blotting using the monoclonal antibody 2D8. To block Aβ generation, CHO-7PA2 cells were treated for 24 h with DAPT before immunoprecipitation. To interfere with PrP^{Sc}-induced toxicity, transfected cells were pretreated for 1 h with the monoclonal anti-PrP antibody 3F4 (1 µg/ml) before co-culture. The antibody was also present during co-cultivation. For quantification of Hsp72, total lysates were analyzed by Western blotting using the monoclonal anti-Hsp72 antibody C92. Chemiluminescence was determined using a Fujifilm LAS-4000 ChemiDot imager and the Multi Gauge V3.0 software, and normalized to β-actin. Values of CHO-7PA2 cells or SH-SY5Y cells overexpressing wild type APP were compared to either CHO cells or mock-transfected SH-SY5Y cells subjected to the same heat shock. Quantifications were based on at least three independent experiments.

Exosome isolation

Conditioned media of ScN2a or N2a cells were centrifuged for 10 min at 3,000xg and ultracentrifuged for 30 min at 10,000xg and for 1 h at 100,000xg as described earlier (Fevrier et al., PNAS, 2003). Pellets were resuspended in

cold detergent buffer A (0.5% Triton X-100, 0.5% sodium deoxycholate in PBS) and digested with Proteinase K for 30 min at 37°C (final concentration 10 µg/ml). Reaction was stopped by the addition of PMSF (final concentration 2 mM) and PrP analyzed by Western blotting using the polyclonal anti-PrP antibody A7.

Luciferase Assays

Co-cultivated SH-SY5Y cells or SH-SY5Y cells cultured in 3.5 cm dishes were transiently transfected with firefly luciferase reporter plasmid (HSE-luc) and subjected to the stress treatment indicated. After 8 h incubation at 37°C cells were lysed in Reporter Lysis Buffer (Promega). Luciferase activity was analyzed luminometrically using the luciferase assay system (Promega) and a LB96V or Mithras LB 940 luminometer (Berthold Technologies, Bad Wildbad, Germany) according to the manufacturer's instruction. The measured values were analyzed using a WinGlow Software (Berthold Technologies). Quantifications were based on at least three independent experiments.

Apoptosis assay and immunofluorescence

For quantification of apoptotic cell death, SH-SY5Y cells were fixed on glass coverslips with 3.7% paraformaldehyde for 20 min, washed and permeabilized with 0.2% Triton-X 100 in PBS for 10 min at room temperature. Fixed cells were incubated with an anti-active caspase-3 antibody overnight at 4°C, followed by an incubation with the secondary antibody fluorescently labeled with Alexa Fluor[®] 555 for 1 h at room temperature. Cells were then mounted onto glass slides and examined by fluorescence microscopy using a Zeiss Axioscope 2 plus microscope (Carl Zeiss). The number of cells positive for activated

caspase-3 from at least 1000 transfected cells was determined in a blinded manner. All quantifications were based on at least three independent experiments. For immunofluorescence analysis of the stress-inducible Hsp72 in N2a or ScN2a or CHO or CHO-7PA2 cells, cells were grown on glass coverslips. At day 2 (CHO/CHO-7PA2) or day 4 (N2a/ScN2a) in culture, cells were subjected to the heat shock indicated, returned to 37°C and analyzed after an additional 8 h or 16 h, respectively. After incubation, cells were fixed, permeabilized and stained for Hsp72 using the monoclonal anti-Hsp72 antibody C92. Nuclei were stained with ToPro. Cells were examined by confocal fluorescence microscopy using a Zeiss Axiovert 200M microscope (Carl Zeiss).

Statistical analysis

Quantifications were based on at least three independent experiments. Data were shown as means \pm S.E.. Statistical analysis was performed using Student's *t* test. P-values are as follows: * $p < 0.05$; ** $p < 0.005$; *** $p < 0.0005$.

RESULTS

The heat shock response is impaired in cell lines chronically exposed to PrP^{Sc} or A β

We previously showed that the HSR in scrapie-infected mouse neuroblastoma (ScN2a) cells, which propagate proteinase K (PK)-resistant PrP^{Sc} and infectious prions (Fig. 1A), is significantly impaired (33,34). The amount of Hsp72, which is expressed at high levels only after heat shock or other forms of metabolic stress (51), is greatly increased in uninfected N2a cells after a heat shock of 10 or 20 min (42 or 44°C), while ScN2a cells do not express

Hsp72 after being subjected to the same stress conditions. This phenomenon is illustrated by Western blotting (Fig. 1C) and indirect immunofluorescence (Fig. 2A, left panel). Prompted by these results we asked whether chronic exposure to another pathogenic protein assembly would also modulate the HSR. To experimentally address this possibility, we made use of a stably transfected Chinese hamster ovary cell line (CHO-7PA2) that expresses the familial AD mutant V717F of the human amyloid precursor protein APP₇₅₁ and secretes A β (46) (Fig. 1B, left panel). Importantly, secreted A β from CHO-7PA2 cells is neurotoxic, demonstrated by its ability to potently inhibit long-term potentiation *in vivo* and to interfere with neuronal viability (48,52,53). In addition, we generated a stably transfected SH-SY5Y cell line expressing wild type human APP. Similarly to the CHO-7PA2 cells SH-SY5Y-wtAPP cells secreted significantly increased levels of A β when compared to the mock transfected control (Fig. 1B, right panel).

To analyze the HSR, we subjected CHO-7PA2 and SH-SY5Y-wtAPP cells to different heat shock conditions and analyzed expression of Hsp72 after the cells had been cultivated for another 8 h at 37°C. The Western blot (Fig. 1D, E) and immunofluorescence analysis (Fig. 2A, right panel) revealed that A β -overexpressing CHO-7PA2 and SH-SY5Y-wtAPP are able to mount a stress response, however, the amount of Hsp72 in stressed CHO-7PA2 and SH-SY5Y-wtAPP was lower when compared to CHO or mock transfected SH-SY5Y cells, respectively, subjected to the same stress conditions. These

differences were significant under all stress conditions tested for the SH-SY5Y cell lines (Fig. 1E), while after more severe stress (42°C or 44°C for 20 min) Hsp72 levels were comparable in CHO and CHO-7PA2 cells (Fig. 1D). Ectopic expression of a mutant of the heat shock transcription factor 1 (Δ HSF), which contains a deletion in the regulatory domain (Δ 202-316) and is constitutively active (38), induced the upregulation of Hsp72 in both ScN2a and CHO-7PA2 cells (Fig. 2B). These findings suggest that the impaired Hsp72 expression after stress is obviously caused by a deregulated HSF1 activation/inactivation pathway and not by mutations in the promoter regions of stress-regulated genes (34). These results demonstrate that cells chronically exposed to A β or PrP^{Sc} have a higher threshold to mount a HSR.

Acute exposure of cells to PrP^{Sc} lowers the threshold for a heat shock response

ScN2a cells had been established from a population of cells acutely infected with prions. Thus, it might well be that an impaired stress response was a selection advantage to counteract adverse effects of PrP^{Sc} on cell viability. We therefore wanted to analyze possible acute effects of PrP^{Sc} on the HSR by employing a novel cell culture assay, which is based on the co-culture of SH-SY5Y cells with N2a or ScN2a cells (47,48). In this context it is important to note that scrapie-infected cells release PrP^{Sc} and infectious prions into the extracellular environment (Fig. 1A, right panel) (54,55). Our experimental set-up allows us to study the HSR in SH-SY5Y cells after transient exposure to

PrP^{Sc} present in the cell culture medium (Fig. 3A). To assess the HSR in a quantitative manner, we used a reporter gene construct (HSE-luc) expressing firefly luciferase under the control of the highly heat-inducible promoter of the human Hsp70B gene (36). After a brief heat shock, transcription of the luciferase gene is induced and luciferase activity can be determined luminometrically (Fig. 3B). First, we examined whether PrP^{Sc} released by ScN2a cells would induce an HSR in co-cultured SH-SY5Y cells. Luciferase activities in SH-SY5Y cells co-cultured with ScN2a cells for 24 h were comparable to those in cells co-cultured with N2a cells, indicating that acute exposure to PrP^{Sc} did apparently not induce the HSR (Fig. 3C).

Next we tested whether acute exposure to PrP^{Sc} modulates the HSR. To this end, we co-cultured HSE-luc-expressing SH-SY5Y cells with ScN2a cells and then subjected them to a brief heat shock (Fig. 3D). SH-SY5Y cells co-cultured with ScN2a cells showed significantly higher luciferase activities after a heat shock than cells co-cultured with N2a cells. For example, a 20 min heat shock at 42°C led to a 8-fold induction of luciferase in SH-SY5Y cells co-cultured with N2a cells, whereas the same heat shock condition led to a 18.5-fold induction in cells pre-exposed to PrP^{Sc} (Fig. 3D). Of note, there was no increase in cell death of co-cultured SH-SY5Y cells under the heat shock conditions applied (Fig. 3E).

Induction of the HSR or increased expression of Hsp72 or clusterin protects against PrP^{Sc}- or A β -induced toxicity

To address the possibility that an induction of the HSR can protect cells from the toxic activity of PrP^{Sc} or A β , we employed a previously established cell culture model (47,48). As illustrated in Fig. 4A (left panel), PrP^{Sc} induces cell death in co-cultured SH-SY5Y cells expressing the cellular prion protein (PrP^C). Similarly, expression of PrP^C sensitizes cells to the toxic effects of A β (Fig. 4B). Toxicity of PrP^{Sc} could be suppressed by performing the co-culture in the presence of the monoclonal anti-PrP antibody 3F4 (Fig. 4A, right panel). Likewise, co-cultivation with CHO-7PA2 cells pre-treated with the γ -secretase inhibitor DAPT did not induce apoptotic cell death in PrP^C-expressing SH-SY5Y cells, indicating that the toxic effect of CHO-7PA2 cells was dependent on the generation of A β (48).

To induce the HSR without a stress treatment, we expressed the constitutively active Δ HSF mutant, which increases expression of many heat shock proteins, for example of Hsp72 (Fig. 2B). SH-SY5Y cells transiently co-transfected with PrP^C and Δ HSF or GFP as a control were co-cultured with ScN2a or CHO-7PA2 cells, and apoptotic cell death was analyzed after 16 h of co-culturing. ScN2a or CHO-7PA2 cells induced cell death in co-cultured SH-SY5Y cells expressing PrP^C and GFP, while the co-expression of Δ HSF protected the cells from PrP^{Sc}- or A β -induced cell death (Fig. 4C). In a next step we tested whether it is sufficient to express individual chaperones to block PrP^{Sc}- or A β -induced toxicity. To analyze chaperones located in different cellular compartments, we chose Hsp72, a cytoplasmic chaperone, and

clusterin, an extracellular chaperone that has recently been genetically associated with AD (56,57). Indeed, expression of either Hsp72 or clusterin was sufficient to inhibit PrP^{Sc}- or A β -induced cell death (Fig. 4D and Fig. 5).

Hsp72 and Δ HSF but not clusterin protect against a neurotoxic PrP mutant

Several PrP mutants can induce neuronal cell death in the absence of infectious prion propagation (rev. in (8)). PrP^C can acquire a neurotoxic potential by deleting the internal hydrophobic domain (HD) (58,59). Similar to PrP^C, PrP Δ HD is glycosylated with complex sugars and linked to the outer leaflet of the plasma membrane via a GPI anchor (35). To assess whether an activated HSR and the expression of chaperones can also interfere with the toxic effects of a pathogenic PrP mutant located at the plasma membrane, we used a cell culture model previously established in our group (47,60). Upon ectopic expression of PrP Δ HD, apoptotic cell death is induced in SH-SY5Y cells. The toxic effects of PrP Δ HD are abrogated by co-expression of PrP^C (Fig. 6A). This activity of PrP^C has been conclusively documented in various transgenic mouse models and cultured cells, however, the underlying mechanisms are elusive (47,58-63). To test a possible protective effect of an activated HSR or of individual chaperones, we co-expressed PrP Δ HD with Δ HSF, or Hsp72, or clusterin. Indeed, co-expression of either Δ HSF or Hsp72 protected cells against PrP Δ HD-induced toxicity (Fig. 6B, C). In contrast, clusterin, which efficiently interfered with PrP^{Sc}- or A β -induced cell death, could not prevent toxic effects

mediated by PrP^ΔHD (Fig. 6D). Importantly, ΔHSF or Hsp72 expression did not reduce PrP^ΔHD protein levels nor did expression of PrP^ΔHD prevent secretion of clusterin.

DISCUSSION

Regulation of the cellular stress response is critical to maintain cellular homeostasis and to protect cells from proteotoxicity. Our results indicate that pathogenic oligomers made from different proteins deregulate the HSR, in particular, they can modify the threshold for the stress-induced expression of heat shock proteins. Furthermore, we present evidence that the toxic effects of three different neurotoxic protein conformers (PrP^{Sc}, Aβ and PrP^ΔHD) can be ameliorated by activating the HSR or by increasing the expression of individual chaperones.

The HSR is modulated by different pathogenic protein assemblies: distinct effects of acute and chronic exposure

PrP^{Sc} and Aβ form pathogenic protein assemblies within the secretory/endosomal pathway and/or at the plasma membrane. Both protein species are released into the extracellular space, where they can form amyloid plaques. To study how chronic exposure of neuronal cells to these aberrantly folded proteins might modulate the HSR, we made use of previously established cell lines generating neurotoxic PrP^{Sc} or Aβ. ScN2a cells represent a well-characterized cell culture model to study pathomechanistic pathways linked to prion diseases. Notably, PK-resistant PrP^{Sc} and infectious prions are released into the cell culture medium. Generation of Aβ

is a physiological process, however, it was previously shown that Aβ secreted into the medium of CHO-7PA2 cells is neurotoxic, demonstrated by its ability to potently inhibit long-term potentiation *in vivo* and to interfere with neuronal viability (48,52,53).

Based on the finding that the HSR response is significantly impaired in ScN2a cells (33,34), we first compared the HSR of CHO to that of CHO-7PA2 cells by analyzing expression of Hsp72, the stress-inducible Hsp70 variant, after moderate, non-lethal heat shock conditions. In contrast to ScN2a cells, CHO-7PA2 cells are able to increase expression of Hsp72 in response to heat shock, however, their efficiency to mount a heat shock response is reduced, which is most evident under mild heat shock conditions. To exclude the possibility that the observed effect is specific for CHO-7PA2 cells or the mutant human APP expressed in this line we show an impaired HSR also in stably transfected SH-SY5Y cell lines overexpressing human wild type APP. Similarly to what we observed in ScN2a cells, forced expression of a constitutively active mutant of HSF1 (ΔHSF) efficiently induced Hsp72 expression in CHO-7PA2 cells. These data agreed that the reduced levels of Hsp72 in CHO-7PA2 cells are not due to mutations in the promoter region of the Hsp72 gene but rather to a modulation of the activation/deactivation pathway of HSF1. Such a scenario is in line with our previous finding that the impaired HSR in ScN2a cells is caused by an accelerated deactivation of HSF1 after stress (34).

With the help of a co-culture model we were able to study acute effects of pathogenic protein conformers on the HSR. Exposure of

SH-SY5Y cells to PrP^{Sc} *per se* did not induce Hsp72 expression, but increased Hsp72 expression in response to heat shock conditions. Mechanistically, it is conceivable that the acute exposure of cells to PrP^{Sc} sensitizes the HSF1 activation pathway thereby lowering the threshold for efficient Hsp72 expression in response to additional stress.

HSF activation/deactivation is regulated in the cytoplasmic and nuclear compartment at multiple steps via the interaction with chaperones and by different posttranslational modifications (rev. in (64)). It is difficult to discriminate whether PrP^{Sc} or A β modulates any of these steps directly by interacting with any of the HSF1 modulators or indirectly via disruption of the proteostasis. Both PrP^{Sc} and A β have been found in the cytoplasmic compartment where they could interact with either HSF1 or chaperones implicated in HSF1 regulation. On the other hand, it has also been shown that accumulation of PrP^{Sc} or A β disrupts the proteostasis network. For example, cytosolic PrP^{Sc} inhibits proteasomal activity (65) and A β interferes with mitochondria function (rev. in (66)).

Activation of the HSR or expression of cytosolic Hsp72 protects against toxic effects of A β , PrP^{Sc} and a neurotoxic PrP mutant

The possibility to harness the stress response therapeutically have been demonstrated in various misfolding disease models previously (22,26,64,67,68). New in our study are the approaches to study the cells' ability to mount a HSR under conditions of acute and chronic exposure to PrP^{Sc} and A β and to analyze three

different neurotoxic proteins under comparable experimental conditions. Moreover, we evaluated the protective effect of individual chaperones located in different cellular compartments. Although the exact mechanisms of how PrP^{Sc}, A β or other pathogenic protein conformers interfere with neuronal function are largely unknown, there appear to be common features. In particular, there is increasing experimental evidence that different toxic protein assemblies are structurally related and can activate similar cellular signaling pathways (6-10,69,70). Notably, it has been shown that the cellular prion protein can serve as a cell surface receptor to mediate toxic signaling of both PrP^{Sc} and A β (47,48,71-85). We cannot exclude the possibility that cytosolic chaperones directly interact with PrP^{Sc} or A β . For example, studies in yeast demonstrated that chaperones can interact with and modulate maintenance and propagation of prions (rev in (86-91)). Similarly, employing *C. elegans* and yeast as models of poly-glutamine-induced toxicity it was shown that cytosolic chaperones can ameliorate toxic effects of aberrantly folded protein conformers (92-96). However, it is also plausible that the protective activity of Δ HSF and Hsp72 expression is based on a modulation of PrP^{Sc}- and A β -induced signaling pathways by cytosolic chaperones. A potential candidate for such an intracellular signaling molecule is the stress-kinase JNK since Hsp72 can alleviate toxic effects of various stressors by suppression of JNK signaling (rev. in (97)). In support of such a scenario are data showing that a JNK inhibitor suppressed toxic effects of PrP^{Sc} (47). A different activity of Hsp72 was recently

described in a mouse model of severe muscular dystrophy. This study indicated that Hsp72 can slow progression of disease by interacting with the sarcoplasmic/endoplasmic reticulum Ca^{2+} -ATPase (SERCA) (98). In this context it is important to note that PrP^{C} can restrict Ca^{2+} -influx into the cell by limiting excessive N-Methyl-D-aspartate (NMDA) receptor activity. Notably, this inhibitory activity of PrP^{C} is lost upon interaction with $\text{A}\beta$ (82,84,99).

Interestingly, an activated HSR and increased Hsp72 expression also efficiently prevented toxic effects of the pathogenic PrP mutant $\text{PrP}^{\Delta\text{HHD}}$. $\text{PrP}^{\Delta\text{HHD}}$ is located at the plasma membrane and does not form protein assemblies related to PrP^{Sc} or $\text{A}\beta$. Different models have been proposed to explain the toxic activity of $\text{PrP}^{\Delta\text{HHD}}$, including the interaction with a yet unidentified receptor or a channel-forming activity of $\text{PrP}^{\Delta\text{HHD}}$ (rev. in (70,100)). Irrespective of the exact mechanism, our results indicate that structurally unrelated pathogenic proteins can activate similar cellular pathways and that $\text{PrP}^{\Delta\text{HHD}}$ toxicity might be related to that of PrP^{Sc} and $\text{A}\beta$.

An extracellular chaperone interferes with PrP^{Sc} - and $\text{A}\beta$ - induced cell death, but not with neurotoxic signaling of a PrP mutant

Our study on clusterin revealed interesting activities of this extracellular chaperone. Similarly to Hsp72, clusterin protected against PrP^{Sc} - and $\text{A}\beta$ -induced toxicity, however it could not interfere with toxic effects of $\text{PrP}^{\Delta\text{HHD}}$ expression.

A variety of activities have been reported for clusterin, including modulation of amyloid formation by interacting with prefibrillar structures (101), clearance of extracellular misfolded proteins (102) and sequestration of oligomeric forms of $\text{A}\beta$ (103). Thus, we suggest that despite a similar protective activity against PrP^{Sc} - and $\text{A}\beta$ -induced toxicity, Hsp72 and clusterin exert different modes of action. While Hsp72 seems to modulate intracellular pathways induced by PrP^{Sc} or $\text{A}\beta$ (see above), clusterin obviously interferes with PrP^{Sc} - and $\text{A}\beta$ -induced toxicity by a direct interaction with the toxic protein assemblies, most likely in the extracellular compartment. As a consequence, PrP^{Sc} or $\text{A}\beta$ no longer interacts with PrP^{C} at the plasma membrane, which in our cell culture model is the major cell surface receptor of PrP^{Sc} - or $\text{A}\beta$ -induced toxicity. The failure of clusterin to interfere with $\text{PrP}^{\Delta\text{HHD}}$ -induced toxicity indirectly supports such a mode of action, since $\text{PrP}^{\Delta\text{HHD}}$ -mediated toxicity seems not to be linked to the formation of β -sheet rich protein assemblies (rev. in (70,100)).

Our findings emphasize complex interrelations between the HSR and neurotoxic proteins. For example, toxic oligomers can both sensitize and desensitize the HSR in a time-dependent manner. As a consequence it might be beneficial to interfere with the HSR at an early phase of the disease, whereas HSR stimulation is a possible strategy at later time points. Indeed, the protective effect of Hsp72 and clusterin supports the concept to use forced expression of individual chaperones or pharmacological

induction of the HSR to delay progression of neurodegenerative disease. In addition, a combination of chaperones promises additive or synergistic effects since different chaperones can target distinct steps in neurotoxic signaling pathways.

REFERENCES

1. Collinge, J. (2001) *Annu Rev Neurosci* **24**, 519-550
2. Prusiner, S. B., Scott, M. R., DeArmond, S. J., and Cohen, F. E. (1998) *Cell* **93**, 337-348
3. Weissmann, C., Fischer, M., Raeber, A., Büeler, H., Sailer, A., Shmerling, D., Rüllicke, T., Brandner, S., and Aguzzi, A. (1996) *Cold Spring Harb Symp Quant Biol* **61**, 511-522
4. Chesebro, B. (2003) *British medical bulletin* **66**, 1-20
5. De Strooper, B. (2010) *Physiol Rev* **90**, 465-494
6. Huang, Y., and Mucke, L. (2012) *Cell* **148**, 1204-1222
7. Eisenberg, D., and Jucker, M. (2012) *Cell* **148**, 1188-1203
8. Winklhofer, K. F., Tatzelt, J., and Haass, C. (2008) *EMBO J* **27**, 336-349
9. Ilieva, H., Polymenidou, M., and Cleveland, D. W. (2009) *J Cell Biol* **187**, 761-772
10. Resenberger, U. K., Winklhofer, K. F., and Tatzelt, J. (2011) *Top Curr Chem* **305**, 101-119
11. Kenward, N., Hope, J., Landon, M., and Mayer, R. J. (1994) *J. Neurochem.* **62**, 1870-1877
12. Freixes, M., Puig, B., Rodriguez, A., Torrejon-Escribano, B., Blanco, R., and Ferrer, I. (2004) *Acta Neuropathol* **108**, 295-301
13. Calero, M., Rostagno, A., Matsubara, E., Zlokovic, B., Frangione, B., and Ghiso, J. (2000) *Microscopy research and technique* **50**, 305-315
14. Hartl, F. U., Bracher, A., and Hayer-Hartl, M. (2011) *Nature* **475**, 324-332
15. Dabbs, R. A., Wyatt, A. R., Yerbury, J. J., Ecroyd, H., and Wilson, M. R. (2011) *Top Curr Chem*
16. Wu, C. (1995) *Annu. Rev. Cell Dev. Biol.* **11**, 441-469
17. Morimoto, R. I., Jurivich, D. A., Kroeger, P. E., Mathur, S. K., S.P., M., Nakai, A., Sarge, K., Abravaya, K., and Sistonen, L. T. (1994) Regulation of heat shock gene transcription by a family of heat shock factors. in *The biology of heat shock proteins and molecular chaperones* (Morimoto, R. I., Tissieres, A., and Georgopoulos, C. eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor. pp 417-455
18. Sharp, F. R., Massa, S. M., and Swanson, R. A. (1999) *Trends Neurosci* **22**, 97-99
19. Beere, H. M. (2004) *J Cell Sci* **117**, 2641-2651
20. Gabai, V. L., Meriin, A. B., Mosser, D. D., Caron, A. W., Rits, S., Shifrin, V. I., and Sherman, M. Y. (1997) *J Biol Chem* **272**, 18033-18037
21. Morimoto, R. I. (2012) *Cold Spring Harb Symp Quant Biol*
22. Balch, W. E., Morimoto, R. I., Dillin, A., and Kelly, J. W. (2008) *Science* **319**, 916-919
23. Westerheide, S. D., and Morimoto, R. I. (2005) *J Biol Chem* **280**, 33097-33100
24. Dai, C., Whitesell, L., Rogers, A. B., and Lindquist, S. (2007) *Cell* **130**, 1005-1018
25. Welch, W. J., and Gambetti, P. (1998) *Nature* **392**, 23-24
26. Lindquist, S. L., and Kelly, J. W. (2011) *Cold Spring Harbor perspectives in biology* **3**
27. Katsuno, M., Sang, C., Adachi, H., Minamiyama, M., Waza, M., Tanaka, F., Doyu, M., and Sobue, G. (2005) *Proc Natl Acad Sci U S A* **102**, 16801-16806
28. Waza, M., Adachi, H., Katsuno, M., Minamiyama, M., Sang, C., Tanaka, F., Inukai, A., Doyu, M., and Sobue, G. (2005) *Nat Med* **11**, 1088-1095
29. Kieran, D., Kalmar, B., Dick, J. R., Riddoch-Contreras, J., Burnstock, G., and Greensmith, L. (2004) *Nat Med* **10**, 402-405
30. Steele, A. D., Hutter, G., Jackson, W. S., Heppner, F. L., Borkowski, A. W., King, O. D., Raymond, G. J., Aguzzi, A., and Lindquist, S. (2008) *Proc Natl Acad Sci U S A* **105**, 13626-13631
31. Butler, D. A., Scott, M. R. D., Bockman, J. M., Borchelt, D. R., Taraboulos, A., Hsiao, K. K., Kingsbury, D. T., and Prusiner, S. B. (1988) *J. Virol.* **62**, 1558-1564

32. Caughey, B., and Raymond, G. J. (1991) *J. Biol. Chem.* **266**, 18217-18223
33. Tatzelt, J., Zuo, J. R., Voellmy, R., Scott, M., Hartl, U., Prusiner, S. B., and Welch, W. J. (1995) *Proc Natl Acad Sci U S A* **92**, 2944-2948
34. Winklhofer, K. F., Reintjes, A., Hoener, M. C., Voellmy, R., and Tatzelt, J. (2001) *J Biol Chem* **276**, 45160-45167
35. Winklhofer, K. F., Heske, J., Heller, U., Reintjes, A., Muranji, W., Moarefi, I., and Tatzelt, J. (2003) *J Biol Chem* **278**, 14961-14970
36. Voellmy, R., Ahmed, A., Schiller, P., Bromley, P., and Rungger, D. (1985) *Proc Natl Acad Sci U S A* **82**, 4949-4953
37. Kharlamov, A., Jones, S. C., and Kim, D. K. (2002) *Experimental brain research. Experimentelle Hirnforschung* **147**, 353-359
38. Zuo, J., Rungger, D., and Voellmy, R. (1995) *Mol Cell Biol* **15**, 4319-4330
39. Humphreys, D., Hochgrebe, T. T., Easterbrook-Smith, S. B., Tenniswood, M. P., and Wilson, M. R. (1997) *Biochemistry* **36**, 15233-15243
40. Kascsak, R. J., Rubenstein, R., Merz, P. A., Tonna-DeMasi, M., Fersko, R., Carp, R. I., Wisniewski, H. M., and Diringer, H. (1987) *J Virol* **61**, 3688-3693
41. Winklhofer, K. F., Heller, U., Reintjes, A., and Tatzelt, J. (2003) *Traffic* **4**, 313-322
42. Welch, W. J., and Suhan, J. P. (1986) *J. Cell Biol.* **103**, 2035-2052
43. Humphreys, D. T., Carver, J. A., Easterbrook-Smith, S. B., and Wilson, M. R. (1999) *J Biol Chem* **274**, 6875-6881
44. Shirotani, K., Tomioka, M., Kremmer, E., Haass, C., and Steiner, H. (2007) *Neurobiol Dis* **27**, 102-107
45. Yamasaki, A., Eimer, S., Okochi, M., Smialowska, A., Kaether, C., Baumeister, R., Haass, C., and Steiner, H. (2006) *J Neurosci* **26**, 3821-3828
46. Podlisny, M. B., Ostaszewski, B. L., Squazzo, S. L., Koo, E. H., Rydell, R. E., Teplow, D. B., and Selkoe, D. J. (1995) *J Biol Chem* **270**, 9564-9570
47. Rambold, A. S., Müller, V., Ron, U., Ben-Tal, N., Winklhofer, K. F., and Tatzelt, J. (2008) *EMBO J* **27**, 1974-1984
48. Resenberger, U. K., Harmeier, A., Woerner, A. C., Goodman, J. L., Muller, V., Krishnan, R., Vabulas, R. M., Kretzschmar, H. A., Lindquist, S., Hartl, F. U., Multhaup, G., Winklhofer, K. F., and Tatzelt, J. (2011) *EMBO J* **30**, 2057-2070
49. Tatzelt, J., Prusiner, S. B., and Welch, W. J. (1996) *EMBO J* **15**, 6363-6373
50. Winklhofer, K. F., and Tatzelt, J. (2000) *Biol Chem* **381**, 463-469
51. Lindquist, S., and Craig, E. A. (1988) *Annual review of genetics* **22**, 631-677
52. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. (2002) *Nature* **416**, 535-539.
53. Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., and Ashe, K. H. (2005) *Nature neuroscience* **8**, 79-84
54. Schätzl, H. M., Laszlo, L., Holtzman, D. M., Tatzelt, J., DeArmond, S. J., Weiner, R. I., Mobley, W. C., and Prusiner, S. B. (1997) *J. Virol.* **71**, 8821-8831
55. Fevrier, B., Vilette, D., Archer, F., Loew, D., Faigle, W., Vidal, M., Laude, H., and Raposo, G. (2004) *Proc Natl Acad Sci U S A* **101**, 9683-9688
56. Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskva, V., Dowzell, K., Williams, A., Jones, N., Thomas, C., Stretton, A., Morgan, A. R., Lovestone, S., Powell, J., Proitsi, P., Lupton, M. K., Brayne, C., Rubinsztein, D. C., Gill, M., Lawlor, B., Lynch, A., Morgan, K., Brown, K. S., Passmore, P. A., Craig, D., McGuinness, B., Todd, S., Holmes, C., Mann, D., Smith, A. D., Love, S., Kehoe, P. G., Hardy, J., Mead, S., Fox, N., Rossor, M., Collinge, J., Maier, W., Jessen, F., Schurmann, B., van den Bussche, H., Heuser, I., Kornhuber, J., Wiltfang, J., Dichgans, M., Frolich, L., Hampel, H., Hull, M., Rujescu, D., Goate, A. M., Kauwe, J. S., Cruchaga, C., Nowotny, P., Morris, J. C., Mayo, K., Sleegers, K., Bettens, K., Engelborghs, S., De Deyn, P. P., Van Broeckhoven, C., Livingston, G., Bass, N. J., Gurling, H., McQuillin, A., Gwilliam, R., Deloukas, P., Al-Chalabi, A., Shaw, C. E., Tzolaki, M., Singleton, A. B., Guerreiro, R., Muhleisen, T. W., Nothen, M. M., Moebus, S., Jockel, K. H., Klopp, N., Wichmann, H. E.,

- Carrasquillo, M. M., Pankratz, V. S., Younkin, S. G., Holmans, P. A., O'Donovan, M., Owen, M. J., and Williams, J. (2009) *Nature genetics* **41**, 1088-1093
57. Lambert, J. C., Heath, S., Even, G., Campion, D., Slegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., Tavernier, B., Letenneur, L., Bettens, K., Berr, C., Pasquier, F., Fievet, N., Barberger-Gateau, P., Engelborghs, S., De Deyn, P., Mateo, I., Franck, A., Helisalmi, S., Porcellini, E., Hanon, O., de Pancorbo, M. M., Lendon, C., Dufouil, C., Jaillard, C., Leveillard, T., Alvarez, V., Bosco, P., Mancuso, M., Panza, F., Nacmias, B., Bossu, P., Piccardi, P., Annoni, G., Seripa, D., Galimberti, D., Hannequin, D., Licastro, F., Soininen, H., Ritchie, K., Blanche, H., Dartigues, J. F., Tzourio, C., Gut, I., Van Broeckhoven, C., Alperovitch, A., Lathrop, M., and Amouyel, P. (2009) *Nature genetics* **41**, 1094-1099
 58. Shmerling, D., Hegyi, I., Fischer, M., Blättler, T., Brandner, S., Götz, J., Rüllicke, T., Flechsig, E., Cozzio, A., von Mehring, C., Hangartner, C., Aguzzi, A., and Weissmann, C. (1998) *Cell* **93**, 203-214
 59. Li, A., Christensen, H. M., Stewart, L. R., Roth, K. A., Chiesa, R., and Harris, D. A. (2007) *EMBO J* **26**, 548-558
 60. Sakthivelu, V., Seidel, R. P., Winklhofer, K. F., and Tatzelt, J. (2011) *J Biol Chem* **286**, 8901-8908
 61. Watts, J. C., Drisaldi, B., Ng, V., Yang, J., Strome, B., Horne, P., Sy, M. S., Yoong, L., Young, R., Mastrangelo, P., Bergeron, C., Fraser, P. E., Carlson, G. A., Mount, H. T., Schmitt-Ulms, G., and Westaway, D. (2007) *EMBO J* **26**, 4038-4050
 62. Solomon, I. H., Huettner, J. E., and Harris, D. A. (2010) *J Biol Chem* **285**, 26719-26726
 63. Massignan, T., Stewart, R. S., Biasini, E., Solomon, I. H., Bonetto, V., Chiesa, R., and Harris, D. A. (2010) *J Biol Chem* **285**, 7752-7765
 64. Anckar, J., and Sistonen, L. (2011) *Annu Rev Biochem* **80**, 1089-1115
 65. Kristiansen, M., Deriziotis, P., Dimcheff, D. E., Jackson, G. S., Ovaa, H., Naumann, H., Clarke, A. R., van Leeuwen, F. W., Menendez-Benito, V., Dantuma, N. P., Portis, J. L., Collinge, J., and Tabrizi, S. J. (2007) *Mol Cell* **26**, 175-188
 66. Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J. W., Xu, H. W., Stern, D., McKhann, G., and Yan, S. D. (2005) *Faseb J* **19**, 2040-2041
 67. Behl, C., and Schubert, D. (1993) *Neurosci Lett* **154**, 1-4
 68. Neef, D. W., Turski, M. L., and Thiele, D. J. (2010) *PLoS Biol* **8**, e1000291
 69. Kaye, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003) *Science* **300**, 486-489
 70. Biasini, E., Turnbaugh, J. A., Unterberger, U., and Harris, D. A. (2012) *Trends Neurosci* **35**, 92-103
 71. Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, A., Kobayashi, Y., Marino, S., Weissmann, C., and Aguzzi, A. (1996) *Nature* **379**, 339-343
 72. Mallucci, G., Dickinson, A., Linehan, J., Klöhn, P. C., Brandner, S., and Collinge, J. (2003) *Science* **302**, 871-874
 73. Chesebro, B., Trifilo, M., Race, R., Meade-White, K., Teng, C., LaCasse, R., Raymond, L., Favara, C., Baron, G., Priola, S., Caughey, B., Masliah, E., and Oldstone, M. (2005) *Science* **308**, 1435-1439
 74. Kudo, W., Lee, H. P., Zou, W. Q., Wang, X., Perry, G., Zhu, X., Smith, M. A., Petersen, R. B., and Lee, H. G. (2012) *Hum Mol Genet* **21**, 1138-1144
 75. Bate, C., and Williams, A. (2011) *J Biol Chem* **286**, 37955-37963
 76. Chung, E., Ji, Y., Sun, Y., Kacsak, R. J., Kacsak, R. B., Mehta, P. D., Strittmatter, S. M., and Wisniewski, T. (2010) *BMC Neurosci* **11**, 130
 77. Caetano, F. A., Beraldo, F. H., Hajj, G. N., Guimaraes, A. L., Jurgensen, S., Wasilewska-Sampaio, A. P., Hirata, P. H., Souza, I., Machado, C. F., Wong, D. Y., De Felice, F. G., Ferreira, S. T., Prado, V. F., Rylett, R. J., Martins, V. R., and Prado, M. A. (2011) *J Neurochem* **117**, 538-553
 78. Barry, A. E., Klyubin, I., Mc Donald, J. M., Mably, A. J., Farrell, M. A., Scott, M., Walsh, D. M., and Rowan, M. J. (2011) *J Neurosci* **31**, 7259-7263

79. Freir, D. B., Nicoll, A. J., Klyubin, I., Panico, S., Mc Donald, J. M., Risse, E., Asante, E. A., Farrow, M. A., Sessions, R. B., Saibil, H. R., Clarke, A. R., Rowan, M. J., Walsh, D. M., and Collinge, J. (2011) *Nat Commun* **2**, 336
80. Lauren, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., and Strittmatter, S. M. (2009) *Nature* **457**, 1128-1132
81. Alier, K., Ma, L., Yang, J., Westaway, D., and Jhamandas, J. H. (2011) *J Neurosci* **31**, 16292-16297
82. You, H., Tsutsui, S., Hameed, S., Kannanayakal, T. J., Chen, L., Xia, P., Engbers, J. D., Lipton, S. A., Stys, P. K., and Zamponi, G. W. (2012) *Proc Natl Acad Sci U S A* **109**, 1737-1742
83. Gimbel, D. A., Nygaard, H. B., Coffey, E. E., Gunther, E. C., Lauren, J., Gimbel, Z. A., and Strittmatter, S. M. (2010) *J Neurosci* **30**, 6367-6374
84. Um, J. W., Nygaard, H. B., Heiss, J. K., Kostylev, M. A., Stagi, M., Vortmeyer, A., Wisniewski, T., Gunther, E. C., and Strittmatter, S. M. (2012) *Nature neuroscience*
85. Beland, M., Motard, J., Barbarin, A., and Roucou, X. (2012) *J Neurosci* **32**, 13255-13263
86. Masison, D. C., Kirkland, P. A., and Sharma, D. (2009) *Prion* **3**, 65-73
87. Romanova, N. V., and Chernoff, Y. O. (2009) *Protein and peptide letters* **16**, 598-605
88. Tuite, M. F., Marchante, R., and Kushnirov, V. (2011) *Top Curr Chem* **305**, 257-298
89. Sweeny, E. A., and Shorter, J. (2008) *Prion* **2**, 135-140
90. Halfmann, R., Alberti, S., and Lindquist, S. (2010) *Trends Cell Biol* **20**, 125-133
91. Liebman, S. W., and Chernoff, Y. O. (2012) *Genetics* **191**, 1041-1072
92. Krobitsch, S., and Lindquist, S. (2000) *Proc Natl Acad Sci U S A* **97**, 1589-1594
93. Muchowski, P. J., Schaffar, G., Sittler, A., Wanker, E. E., Hayer-Hartl, M. K., and Hartl, F. U. (2000) *Proc Natl Acad Sci U S A* **97**, 7841-7846
94. Gokhale, K. C., Newnam, G. P., Sherman, M. Y., and Chernoff, Y. O. (2005) *J Biol Chem* **280**, 22809-22818
95. Prahla, V., and Morimoto, R. I. (2011) *Proc Natl Acad Sci U S A* **108**, 14204-14209
96. Satyal, S. H., Schmidt, E., Kitagawa, K., Sondheimer, N., Lindquist, S., Kramer, J. M., and Morimoto, R. I. (2000) *Proc Natl Acad Sci U S A* **97**, 5750-5755
97. Gabai, V. L., Meriin, A. B., Yaglom, J. A., Volloch, V. Z., and Sherman, M. Y. (1998) *FEBS Lett* **438**, 1-4
98. Gehrig, S. M., van der Poel, C., Sayer, T. A., Schertzer, J. D., Henstridge, D. C., Church, J. E., Lamon, S., Russell, A. P., Davies, K. E., Febbraio, M. A., and Lynch, G. S. (2012) *Nature*
99. Khosravani, H., Zhang, Y., Tsutsui, S., Hameed, S., Altier, C., Hamid, J., Chen, L., Villemaire, M., Ali, Z., Jirik, F. R., and Zamponi, G. W. (2008) *J Cell Biol* **181**, 551-565
100. Solomon, I. H., Schepker, J. A., and Harris, D. A. (2010) *Curr Issues Mol Biol* **12**, 51-61
101. Yerbury, J. J., Poon, S., Meehan, S., Thompson, B., Kumita, J. R., Dobson, C. M., and Wilson, M. R. (2007) *Faseb J* **21**, 2312-2322
102. Wyatt, A. R., Yerbury, J. J., Berghofer, P., Greguric, I., Katsifis, A., Dobson, C. M., and Wilson, M. R. (2011) *Cellular and molecular life sciences : CMLS* **68**, 3919-3931
103. Narayan, P., Orte, A., Clarke, R. W., Bolognesi, B., Hook, S., Ganzinger, K. A., Meehan, S., Wilson, M. R., Dobson, C. M., and Klenerman, D. (2012) *Nat Struct Mol Biol* **19**, 79-83

FOOTNOTES

The work was supported by grants from the Deutsche Forschungsgemeinschaft (SFB 596, GRK1123 to GM and SFB 740 to LMM and GM) and the Max Planck Society. We thank Rick Morimoto for the Hsp72 construct, Richard Voellmy for the wtHSF and Δ HSF constructs and Christian Haass for the A β antibodies.

FIGURE LEGENDS

Figure 1. Impaired heat shock response in cell lines chronically exposed to PrP^{Sc} or A β

(A) Chronically scrapie-infected N2a cells (ScN2a) are characterized by the formation of Proteinase K (PK)-resistant scrapie prion protein (PrP^{Sc}). Total cell lysates and isolated exosomes prepared from N2a or ScN2a cells were treated with PK or left untreated and then analyzed by Western blotting using the polyclonal anti-PrP antibody A7. (B) Stably transfected CHO cells (CHO-7PA2) or SH-SY5Y cells generate amyloid beta (A β). A β present in conditioned medium of CHO or CHO-7PA2 cells and stably transfected SH-SY5Y cells was analyzed by immunoprecipitation with the polyclonal antibody 3552 followed by Western blotting using the monoclonal antibody 2D8. To block A β generation, CHO-7PA2 cells were treated for 24 h with DAPT before immunoprecipitation. (C-E) ScN2a, CHO-7PA2 and stably transfected SH-SY5Y cells exhibit an impaired heat shock response. (C) N2a and ScN2a cells were subjected to heat shock conditions as indicated. The stress-inducible heat shock protein Hsp72 was analyzed by Western blotting using the monoclonal anti-Hsp72 antibody C92. (D) CHO and CHO-7PA2 cells were subjected to heat shock conditions as indicated. The stress-inducible heat shock protein Hsp72 was analyzed by Western blotting using the monoclonal anti-Hsp72 antibody C92. Band intensities of the Hsp72 signals from CHO and CHO-7PA2 cells were quantified and normalized to β -actin. The fold induction of Hsp72 in CHO-7PA2 cells in response to various stresses, relative to CHO cells is shown in the right panel. (E) Mock- and wild type APP-transfected SH-SY5Y cells were subjected to heat shock conditions as indicated. The stress-inducible heat shock protein Hsp72 was analyzed as described under Fig. 1D. The relative amounts of Hsp72 are represented as the mean \pm S.E. of three to four independent experiments. * p < 0,05.

Figure 2. Cells chronically exposed to PrP^{Sc} or A β exhibit a higher threshold to mount a heat shock response

(A) ScN2a and CHO-7PA2 cells have an impaired heat shock response. N2a, ScN2a, CHO and CHO-7PA2 cells were subjected to the heat shock conditions as indicated. Hsp72 was analyzed by indirect immunofluorescence using the monoclonal anti-Hsp72 antibody C92. (B) Expression of a constitutively active mutant of the heat shock transcription factor 1 (Δ HSF) induces expression of Hsp72 in both ScN2a and CHO-7PA2 cells. N2a, ScN2a, CHO and CHO-7PA2 cells were transiently transfected with wild type HSF (wtHSF) or the constitutively active Δ HSF mutant. 24 h after transfection expression of Hsp72 was analyzed by indirect immunofluorescence as described under Fig. 2A. Nuclei were stained with ToPro. Scale bars 10 μ m.

Figure 3. Acute exposure to PrP^{Sc} lowers the threshold for a heat shock response

(A) Schematic model of the co-culture assay. SH-SY5Y cells were plated on glass coverslips. 2 h after transfection, coverslips were transferred into dishes containing a 90% confluent layer of either ScN2a or N2a cells. After 24 h of co-culture, the coverslips were removed and the SH-SY5Y cells analyzed. Either luciferase activity was determined in cell lysates (B, C, D), or SH-SY5Y cells were fixed, permeabilized and stained for active caspase-3 to assess apoptotic cell death (E). All quantifications were based on at least three independent experiments. (B) Heat shock induces expression of luciferase. SH-SY5Y cells were transiently transfected with a reporter gene construct (HSE-luc) expressing firefly luciferase under the control of the highly heat-inducible promoter of the human Hsp70B gene. 18 h after transfection cells were subjected to a heat shock (42°C) for the time indicated, or held at 37°C. After additional 8 h at 37°C luciferase activity in total cell lysates was determined luminometrically and plotted as fold induction relative to cells held at 37°C. (C) Acute exposure to PrP^{Sc} does not induce a heat shock response. SH-SY5Y cells transiently transfected with HSE-luc were co-cultured with ScN2a or N2a cells for 24 h at 37°C and then luciferase activity was analyzed; fold induction relative to cells co-cultured with N2a cells at 37°C is plotted. (D) Acute exposure to PrP^{Sc} lowers the threshold for a stress response. SH-SY5Y cells transiently transfected with HSE-luc were co-cultured with ScN2a or N2a cells for 16 h at 37°C. Cells were subjected to a heat shock (42°C) for the time indicated, or held at 37°C. After additional 8 h at 37°C luciferase activity was analyzed as described above. The fold induction relative to cells co-cultured with N2a cells at 37°C is plotted. (E) Apoptotic cell death is not increased by the heat shock conditions tested. SH-SY5Y cells were co-cultured with ScN2a or N2a cells and heat shocked as described under (D). For quantification of apoptotic cell death, SH-SY5Y cells were fixed, permeabilized and stained for active caspase-3. n.s. non significant; * p < 0,05; ** p < 0,005; *** p < 0,0005.

Figure 4. Induction of the heat shock response or increased expression of Hsp72 protects against PrP^{Sc}- and A β -induced toxicity

(A) Scrapie prions induce apoptosis in SH-SY5Y cells expressing PrP^C. SH-SY5Y cells expressing the cellular prion protein (PrP^C) were co-cultured with ScN2a or N2a cells in the presence or absence of the monoclonal anti-PrP antibody 3F4. (B) A β secreted by stably transfected cells is toxic to cells expressing PrP^C. SH-SY5Y cells expressing PrP^C were co-cultured with the indicated cell lines. (C) Expression of a constitutively active HSF1 mutant (Δ HSF) protects against PrP^{Sc}- and A β -induced toxicity. SH-SY5Y cells co-expressing PrP^C and Δ HSF were co-cultivated with the indicated cell lines. (D) Expression of a Hsp70 variant protects against PrP^{Sc}- and A β -induced toxicity. SH-SY5Y cells co-expressing PrP^C and Hsp72 were co-cultivated with the indicated cell lines. In (A-D) after 16 h of co-culture, apoptotic cell death in SH-SY5Y cells was determined as described in Experimental Procedures. Expression of PrP and Hsp72 were analyzed by Western blotting using the monoclonal

anti-PrP antibody 3F4 or the monoclonal anti-Hsp72 antibody C92, respectively. n.s. non significant; * $p < 0,05$; ** $p < 0,005$; *** $p < 0,0005$.

Figure 5. Expression of the extracellular chaperone clusterin protects against PrP^{Sc}- and A β -induced toxicity

Expression of the extracellular chaperone clusterin prevents PrP^{Sc}- and A β -induced toxicity. SH-SY5Y cells co-expressing PrP^C and clusterin were co-cultivated with the indicated cell lines. After 16 h of co-culture, apoptotic cell death in SH-SY5Y cells was determined as described in Experimental Procedures. Expression of PrP was analyzed by Western blotting using the monoclonal anti-PrP antibody 3F4. Secretion of clusterin in conditioned media was determined by TCA-precipitation followed by Western blotting using the monoclonal anti-clusterin antibody 41D. n.s. non significant; ** $p < 0,005$; *** $p < 0,0005$.

Figure 6. Hsp72 and Δ Hsf1 but not clusterin protect against a neurotoxic PrP mutant

(A) Expression of PrP^C protects against PrP Δ HD-induced toxicity. (B, C) Hsp72 or Δ Hsf1 interferes with PrP Δ HD-induced toxicity. (D) The extracellular chaperone clusterin does not prevent toxic effects of PrP Δ HD. In (A-D) apoptotic cell death in SH-SY5Y cells expressing the indicated proteins was determined as described in Experimental Procedures. Expression of PrP and PrP Δ HD or Hsp72 was analyzed by Western blotting using the monoclonal anti-PrP antibody 3F4 or the monoclonal anti-Hsp72 antibody C92. Presence of clusterin in conditioned media was determined by TCA-precipitation followed by Western blotting using the monoclonal anti-clusterin antibody 41D. n.s. non significant; ** $p < 0,005$; *** $p < 0,0005$.











